CL2015003023A1 - Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. - Google Patents

Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.

Info

Publication number
CL2015003023A1
CL2015003023A1 CL2015003023A CL2015003023A CL2015003023A1 CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1 CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1
Authority
CL
Chile
Prior art keywords
bimatoprost
sustained release
prostamides
prostaglandins
analogs
Prior art date
Application number
CL2015003023A
Other languages
English (en)
Spanish (es)
Inventor
Scott M Whitcup
David F Woodward
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2015003023A1 publication Critical patent/CL2015003023A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
CL2015003023A 2013-04-12 2015-10-09 Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. CL2015003023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
CL2015003023A1 true CL2015003023A1 (es) 2016-06-10

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003023A CL2015003023A1 (es) 2013-04-12 2015-10-09 Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.

Country Status (18)

Country Link
US (2) US20140308354A1 (https=)
EP (2) EP3656375A1 (https=)
JP (1) JP2016520561A (https=)
KR (1) KR20150141972A (https=)
CN (2) CN110840899A (https=)
AU (2) AU2014250937A1 (https=)
BR (1) BR112015025915A8 (https=)
CA (1) CA2908731A1 (https=)
CL (1) CL2015003023A1 (https=)
DK (1) DK2983663T3 (https=)
ES (1) ES2785382T3 (https=)
IL (1) IL242006B (https=)
MX (1) MX381097B (https=)
MY (1) MY187802A (https=)
RU (1) RU2015143859A (https=)
SG (2) SG10201701938PA (https=)
WO (1) WO2014169075A1 (https=)
ZA (1) ZA201507217B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385254B (es) * 2015-04-30 2025-03-14 Allergan Inc Uso de analogos de bimatoprost para el tratamiento de la reduccion de grasa corporal en un sujeto.
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
TW202216159A (zh) * 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
WO2024218609A1 (en) * 2023-04-18 2024-10-24 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CA2221110C (en) * 1995-05-18 2009-08-04 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
DK1562604T3 (da) 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
EP1699432A2 (en) * 2003-12-22 2006-09-13 Aventis Pharmaceuticals, Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ,インク. 甲状腺眼症の治療のための方法、組成物及び製剤
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2012012546A2 (en) 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
WO2014143754A2 (en) * 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
MX385254B (es) 2015-04-30 2025-03-14 Allergan Inc Uso de analogos de bimatoprost para el tratamiento de la reduccion de grasa corporal en un sujeto.

Also Published As

Publication number Publication date
US20140308354A1 (en) 2014-10-16
BR112015025915A8 (pt) 2020-01-14
RU2015143859A (ru) 2017-05-16
SG10201701938PA (en) 2017-04-27
CN110840899A (zh) 2020-02-28
NZ712804A (en) 2021-02-26
IL242006B (en) 2020-04-30
CA2908731A1 (en) 2014-10-16
DK2983663T3 (da) 2020-04-20
JP2016520561A (ja) 2016-07-14
MX2015014320A (es) 2015-12-08
AU2014250937A1 (en) 2015-10-22
AU2019203214A1 (en) 2019-05-30
MX381097B (es) 2025-03-12
RU2015143859A3 (https=) 2018-03-05
EP3656375A1 (en) 2020-05-27
KR20150141972A (ko) 2015-12-21
WO2014169075A1 (en) 2014-10-16
CN105101962A (zh) 2015-11-25
EP2983663B1 (en) 2020-01-22
US20160339039A1 (en) 2016-11-24
SG10202109919PA (en) 2021-10-28
HK1221406A1 (en) 2017-06-02
BR112015025915A2 (pt) 2017-07-25
EP2983663A1 (en) 2016-02-17
US10682361B2 (en) 2020-06-16
ZA201507217B (en) 2017-09-27
MY187802A (en) 2021-10-26
AU2019203214B2 (en) 2020-10-29
ES2785382T3 (es) 2020-10-06

Similar Documents

Publication Publication Date Title
CL2015003270A1 (es) Composiciones y métodos para el suministro tópico de prostaglandinas a la grasa subcutanea.
CR20130639A (es) Sistemas y métodos basados en tomografía de coherencia óptica y presión
BR112014024903A2 (pt) anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
CO2018002026A2 (es) Composiciones de insulina de rápida acción
MX2016003431A (es) Metodo para producir alcoholes fragantes.
CL2016002531A1 (es) Composición de ácidos grasos monoinsaturados de cadena larga y métodos para la producción de la misma
CR20160061A (es) Formulación estable líquida de etelcalcetide (amg 461)
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
DOP2013000293A (es) Composiciones líquidas de limpieza de sal
CL2015003023A1 (es) Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
EP2964722A4 (en) PROCESS FOR PROVIDING QUANTUM POINTS (QD)
TWD187972S (zh) 泵桿式制動器
CL2015001559A1 (es) Dispersión solida de un modulador selectivo de los receptores de progesterona
BR112013019924A8 (pt) Composições para cuidado oral
EP3009429A4 (en) TYPE R RESVERATROLDIMER, MANUFACTURING METHOD AND USE THEREOF IN REDUCING BLOOD SUGAR
CO2017005843A2 (es) Método para reducir las grasas totales y saturadas en rellenos de productos de confitería
UY35823A (es) Profármacos de antagonista de nmda
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
HRP20181555T1 (hr) Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
CL2016001062A1 (es) Composiciones y métodos para administración de una enzima a las vías respiratorias de un sujeto
MX2016009167A (es) Metodo de tratamiento basado en combinacion.